Kimia Biosciences Falls to 52-Week Low of Rs.28.4 Amidst Continued Downtrend

Stock Price Movement and Volatility

On 28 Nov 2025, Kimia Biosciences recorded an intraday low of Rs.28.4, representing the lowest price level for the stock in the past year. The share price fluctuated between a high of Rs.31.57 and the low of Rs.28.4 during the trading session, reflecting an intraday volatility of 5.27% based on the weighted average price. The stock closed with a day change of -4.59%, underperforming the Pharmaceuticals & Biotechnology sector by approximately 5.02% on the same day.

This decline follows a two-day losing streak, during which the stock has delivered a cumulative return of -9.09%. The current price level is below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating sustained downward pressure over multiple time horizons.

Comparison with Market Benchmarks

While Kimia Biosciences has faced a challenging period, the broader market has shown resilience. The Sensex opened flat but moved into positive territory, trading at 85,744.14 points, a marginal gain of 0.03%. The benchmark index remains close to its 52-week high of 86,055.86, with a distance of just 0.36%. The Sensex is supported by bullish moving averages, with the 50-day moving average positioned above the 200-day moving average, signalling a generally positive market trend. Mega-cap stocks have been leading the gains, contrasting with the performance of Kimia Biosciences.

Long-Term Performance and Financial Metrics

Over the past year, Kimia Biosciences has recorded a total return of -38.31%, significantly lagging behind the Sensex’s 8.47% gain during the same period. The stock’s 52-week high was Rs.86.85, highlighting the extent of the decline to the current low of Rs.28.4.

Financially, the company has exhibited modest growth in net sales, with an annual rate of 2.55% over the last five years. Operating profit has shown a rate of 18.34% during the same period. However, the company carries a high debt burden, with an average debt-to-equity ratio of 14.13 times, which is considerably elevated compared to industry norms.

The return on capital employed (ROCE) averaged 9.76%, indicating relatively low profitability per unit of total capital invested, including both equity and debt. This figure contrasts with the sector’s generally higher ROCE levels, reflecting challenges in generating efficient returns.

Recent Quarterly and Half-Yearly Results

The latest six-month period ending September 2025 showed a profit after tax (PAT) of Rs.1.62 crore, reflecting a contraction of 46.89% compared to the previous corresponding period. Quarterly earnings before depreciation, interest, and taxes (PBDIT) stood at Rs.2.52 crore, marking the lowest level recorded in recent quarters.

The operating profit to net sales ratio for the quarter was 7.41%, also the lowest in recent periods, indicating pressure on operational profitability. These figures highlight subdued earnings performance amid the broader challenges faced by the company.

Consistent Underperformance Relative to Benchmarks

Kimia Biosciences has consistently underperformed the BSE500 index over the last three annual periods. The stock’s returns over the past year were negative at -37.67%, further emphasising the divergence from broader market trends. This persistent underperformance has contributed to the stock’s current valuation levels and price trajectory.

Valuation and Peer Comparison

Despite the recent price decline, Kimia Biosciences exhibits an attractive valuation metric with an enterprise value to capital employed ratio of 3.8. The company’s ROCE of 31.1, calculated on a different basis, suggests some valuation appeal relative to capital utilisation. The stock is trading at a discount compared to the average historical valuations of its peers in the Pharmaceuticals & Biotechnology sector.

Over the past year, while the stock price has declined by 37.67%, the company’s profits have risen by 182.1%, resulting in a price-to-earnings-to-growth (PEG) ratio of 0.1. This divergence between profit growth and stock price movement reflects complex market dynamics and investor sentiment.

Shareholding and Industry Context

The majority shareholding in Kimia Biosciences is held by promoters, maintaining significant control over the company’s strategic direction. The firm operates within the Pharmaceuticals & Biotechnology industry, a sector characterised by innovation, regulatory complexities, and competitive pressures.

While the broader sector has shown resilience and growth, Kimia Biosciences’ stock performance and financial metrics indicate challenges in aligning with sector trends and investor expectations.

Summary of Key Price and Performance Indicators

To summarise, Kimia Biosciences’ stock has reached a 52-week low of Rs.28.4, with a day’s high of Rs.31.57 and an intraday volatility of 5.27%. The stock’s recent two-day return stands at -9.09%, and it trades below all major moving averages. Over the past year, the stock’s total return is -38.31%, contrasting with the Sensex’s positive 8.47% return. Financial indicators reveal modest sales growth, high leverage, and subdued profitability metrics.

These factors collectively provide a comprehensive view of the stock’s current position within the market and its recent price behaviour.

Get 1 year of Weekly Picks FREE when you subscribe to MojoOne. Offer ends soon. Start Saving Now →